• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CXCL8-CXCR1/2轴作为乳腺癌干细胞样细胞的治疗靶点

The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells.

作者信息

Ruffini Pier Adelchi

机构信息

Research and Development Department, Dompé farmaceutici S.p.A., Milan, Italy.

出版信息

Front Oncol. 2019 Feb 6;9:40. doi: 10.3389/fonc.2019.00040. eCollection 2019.

DOI:10.3389/fonc.2019.00040
PMID:30788286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6373429/
Abstract

Cancer stem-like cells (CSC) have been targeted by different strategies over the last decade. This mini review focuses on preclinical and clinical results obtained by interfering with chemokine receptors CXCR1 and CXCR2 in breast cancer. This strategy is currently being tested in a randomized, double blind phase 2 clinical trial.

摘要

在过去十年中，癌症干细胞（CSC）已成为不同治疗策略的靶点。这篇小型综述聚焦于通过干扰乳腺癌中的趋化因子受体CXCR1和CXCR2所取得的临床前和临床研究成果。目前，该策略正在一项随机、双盲的2期临床试验中进行测试。

相似文献

1
The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells.CXCL8-CXCR1/2轴作为乳腺癌干细胞样细胞的治疗靶点
Front Oncol. 2019 Feb 6;9:40. doi: 10.3389/fonc.2019.00040. eCollection 2019.
2
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.CXCL8-CXCR1/2轴在癌症和炎症性疾病中的作用。
Theranostics. 2017 Apr 7;7(6):1543-1588. doi: 10.7150/thno.15625. eCollection 2017.
3
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.一项在可手术的 HER-2 阴性乳腺癌中进行的 CXCR1/2 抑制剂瑞派替尼的机会窗试验。
Breast Cancer Res. 2020 Jan 10;22(1):4. doi: 10.1186/s13058-019-1243-8.
4
Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer.CXCL8/CXCR1/R2信号轴在浸润性乳腺癌患者中的临床意义
Oncol Lett. 2024 Apr 10;27(6):260. doi: 10.3892/ol.2024.14393. eCollection 2024 Jun.
5
Fine-Tuning of GPCR-Chemokine Interactions. Design and Identification of Chemokine Analogues as Receptor Agonists, Biased Agonists, and Antagonists.GPCR-趋化因子相互作用的微调。趋化因子类似物作为受体激动剂、偏向激动剂和拮抗剂的设计与鉴定。
Biochemistry. 2019 Mar 12;58(10):1432-1439. doi: 10.1021/acs.biochem.8b01266. Epub 2019 Feb 21.
6
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.CXCL8受体CXCR1和CXCR2的功能活性对人类恶性黑色素瘤进展的影响
Eur J Cancer. 2009 Sep;45(14):2618-27. doi: 10.1016/j.ejca.2009.07.007. Epub 2009 Aug 13.
7
The CXCL8-CXCR1/2 pathways in cancer.癌症中的CXCL8-CXCR1/2信号通路。
Cytokine Growth Factor Rev. 2016 Oct;31:61-71. doi: 10.1016/j.cytogfr.2016.08.002. Epub 2016 Aug 25.
8
Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina.CXCL8、CXCR1和CXCR2在人和兔视网膜神经元及神经胶质细胞中的表达。
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4578-89. doi: 10.1167/iovs.08-1887. Epub 2008 Jun 14.
9
CXCL8-induced FAK phosphorylation via CXCR1 and CXCR2: cytoskeleton- and integrin-related mechanisms converge with FAK regulatory pathways in a receptor-specific manner.CXCL8通过CXCR1和CXCR2诱导粘着斑激酶（FAK）磷酸化：细胞骨架和整合素相关机制以受体特异性方式与FAK调节途径汇聚。
Cytokine. 2006 Jan 7;33(1):1-16. doi: 10.1016/j.cyto.2005.11.006. Epub 2006 Jan 9.
10
Blockade of Neutrophil's Chemokine Receptors CXCR1/2 Abrogate Liver Damage in Acute-on-Chronic Liver Failure.阻断中性粒细胞趋化因子受体CXCR1/2可减轻慢加急性肝衰竭中的肝损伤。
Front Immunol. 2017 Apr 24;8:464. doi: 10.3389/fimmu.2017.00464. eCollection 2017.

引用本文的文献

1
Targeting CSC-immune cell crosstalk to overcome chemoresistance and enhance immunotherapy efficacy.靶向癌症干细胞-免疫细胞间的相互作用以克服化疗耐药性并提高免疫治疗疗效。
Front Immunol. 2025 Jul 23;16:1620807. doi: 10.3389/fimmu.2025.1620807. eCollection 2025.
2
3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation.三维生物打印三阴性乳腺癌干细胞肿瘤微环境模型用于临床前靶向治疗评估。
ACS Appl Mater Interfaces. 2024 May 29;16(21):27151-27163. doi: 10.1021/acsami.4c04135. Epub 2024 May 19.
3
The small extracellular vesicle-mediated intercellular transformation of CXCR1 to CXCR1 tumour cells promotes the progression of head and neck squamous cell carcinoma.小细胞外囊泡介导的 CXCR1 向 CXCR1 肿瘤细胞的细胞间转化促进头颈部鳞状细胞癌的进展。
J Extracell Vesicles. 2024 Apr;13(4):e12427. doi: 10.1002/jev2.12427.
4
Identification of a Salt Bridge That Is Functionally Important for Chemokine Receptor CXCR1 but not CXCR2.鉴定对趋化因子受体CXCR1具有功能重要性但对CXCR2没有功能重要性的盐桥。
ACS Pharmacol Transl Sci. 2023 Jul 14;6(8):1120-1128. doi: 10.1021/acsptsci.3c00070. eCollection 2023 Aug 11.
5
CXCL8 and the peritoneal metastasis of ovarian and gastric cancer.CXCL8 与卵巢癌和胃癌的腹膜转移。
Front Immunol. 2023 Jun 12;14:1159061. doi: 10.3389/fimmu.2023.1159061. eCollection 2023.
6
CXC ELR-Positive Chemokines as Diagnostic and Prognostic Markers for Breast Cancer Patients.CXC ELR阳性趋化因子作为乳腺癌患者的诊断和预后标志物
Cancers (Basel). 2023 Jun 8;15(12):3118. doi: 10.3390/cancers15123118.
7
A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2- Breast Cancer.由STAT3和p65调控的肿瘤微环境驱动网络对人HR+/HER2-乳腺癌中癌症干细胞的富集起负向调控作用。
Cancers (Basel). 2023 Apr 12;15(8):2255. doi: 10.3390/cancers15082255.
8
The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance.细胞外囊泡和白细胞介素-8在调节和介导中性粒细胞依赖性癌症耐药中的作用。
Front Oncol. 2022 Dec 16;12:947183. doi: 10.3389/fonc.2022.947183. eCollection 2022.
9
Potential of blood exosomal ENAH, SEPT9, EGF, MMP-9 and CXCL8 for the early screening of breast cancer.血液外泌体中ENAH、SEPT9、表皮生长因子（EGF）、基质金属蛋白酶-9（MMP-9）和CXC趋化因子配体8（CXCL8）用于乳腺癌早期筛查的潜力
Oncol Lett. 2022 Nov 3;24(6):460. doi: 10.3892/ol.2022.13580. eCollection 2022 Dec.
10
Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.Siglec-15 作为人类骨巨细胞瘤的新治疗靶点
Curr Oncol. 2022 Oct 13;29(10):7655-7671. doi: 10.3390/curroncol29100605.

本文引用的文献

1
Targeting Cancer Stemness in the Clinic: From Hype to Hope.靶向肿瘤干细胞：从炒作到希望。
Cell Stem Cell. 2019 Jan 3;24(1):25-40. doi: 10.1016/j.stem.2018.11.017. Epub 2018 Dec 27.
2
New Opportunities and Challenges to Defeat Cancer Stem Cells.战胜癌症干细胞的新机遇与挑战。
Trends Cancer. 2017 Nov;3(11):780-796. doi: 10.1016/j.trecan.2017.08.007. Epub 2017 Sep 21.
3
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.评价雷帕霉素与每周紫杉醇联合治疗人表皮生长因子受体-2 阴性转移性乳腺癌患者的 Ib 期临床试验。
Clin Cancer Res. 2017 Sep 15;23(18):5358-5365. doi: 10.1158/1078-0432.CCR-16-2748. Epub 2017 May 24.
4
Multiple anti-tumor effects of Reparixin on thyroid cancer.瑞帕霉素对甲状腺癌的多种抗肿瘤作用。
Oncotarget. 2017 May 30;8(22):35946-35961. doi: 10.18632/oncotarget.16412.
5
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.拉达瑞辛，一种双CXCR1/2抑制剂，通过影响恶性细胞和肿瘤微环境，减轻携带不同分子缺陷的实验性黑色素瘤。
Oncotarget. 2017 Feb 28;8(9):14428-14442. doi: 10.18632/oncotarget.14803.
6
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.在接受化疗的转移性乳腺癌患者中，“新发”转移灶比已存在转移灶的生长与更差的预后相关。
Breast Cancer Res. 2015 Dec 9;17(1):150. doi: 10.1186/s13058-015-0657-1.
7
Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.靶向乳腺癌干细胞上的CXCR1：信号通路与临床应用建模
Oncotarget. 2015 Dec 22;6(41):43375-94. doi: 10.18632/oncotarget.6234.
8
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.缺氧诱导因子是乳腺癌干细胞化疗耐药所必需的。
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38. doi: 10.1073/pnas.1421438111. Epub 2014 Dec 1.
9
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.循环肿瘤细胞作为转移性播散有限的乳腺癌患者转移性扩散的早期预测指标。
Breast Cancer Res. 2014 Sep 16;16(5):440. doi: 10.1186/s13058-014-0440-8.
10
The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases.白细胞介素-8/趋化因子受体1轴与癌症干细胞样特性相关，并与人胰腺癌病例的临床预后相关。
Sci Rep. 2014 Aug 1;4:5911. doi: 10.1038/srep05911.